Rosales-Rivera LY, Velasco-Ramírez SF, Ramírez-Anguiano AC, Sánchez-Peña MJ, González-Ortíz LJ, Bitzer-Quintero OK

Idioma: Español
Referencias bibliográficas: 27
Paginas: 54-59
Archivo PDF: 86.60 Kb.

RESUMEN

El autismo es un grupo de trastornos caracterizados por déficit de desarrollo, grave, permanente y profundo; en el cual se ve afectada directamente la interacción social, comunicación, planificación, imaginación y reciprocidad emocional. Dentro de los mecanismos involucrados para su desarrollo se ha propuesto el deterioro y/o disfunción de los sistemas de neurotransmisión. Se estima que la cuarta parte de pacientes con autismo padecen de ataques epilépticos. Previamente hemos descrito el impacto que tiene el sistema inmune durante las convulsiones; en el autismo se han mostrado alteraciones, con una desregulación en algunas citocinas proinflamatorias y participación de diferentes células del sistema inmune, tanto del sistema nervioso, como de la periferia. Además existen otros mecanismos como factores genéticos que participan en el podado de las sinapsis durante el desarrollo neurológico; sin embargo, aún se desconoce de qué manera interactúan estos factores en el autismo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Holt R, Monaco AP. Links between genetics and pathphysiology in the autism spectrum disorders. EMBO Mol Med 2011;3(8):438-50.

2. Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011;2011: 297153.

3. Fassio A, Patry L, Congia S, Onofri F, Piton A, Gauthier J, et al. SYN1 loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function. Hum Mol Genet 2011; 20(12):2297-307.

4. Lord C. Autism: from research to practice. Am Psychol 2010; 65(8):815-26.

5. Chevallier C, Kohis G, Trolani V, Brodkin ES, Schultz RT. The social motivation theor y of autism. Trends Cogn Sci 2012;16(4):231-9.

6. Chaste P, Leboyer M. Autism risk factors: genes, environment and gene-environment interactions. Dialogues Clin Neurosci 2012;14(3):281-92.

7. Carlson GC. Glutamate receptor dysfunction and drugs targets across models of autism spectrum disorders. Pharmacol Biochem Behav 2012;100(4):850-4.

8. Just MA, Keller TA, Malave VL, Kana RK, Varma S. Autism as a neural systems disorder: a theor y of frontal-posterior underconnectivity. Neurosci Biobehav Rev 2012;36(4):1292-313.

9. Evans B. How autism became autism: the radical transformation of a central concept of child development in Britain. Hist Human Sci 2013;26(3):3-31.

10. Lord C, Jones RM. Annual research review: re-thinking the classification of autism spectrum disorders. J Child Psychol Psychiatry 2012;53(5):490-509.

11. Rodriguez JI, Kern JK. Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol 2011;7(2-4):205-13.

12. Torres AR. Is fever suppression involved in the etiology of autism and neurodevelopmental disorders? BMC Pediatr 2003;3:9.

13. Onore Ch, Carega M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012;26(3):383-92.

14. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van Der Water J. Altered T cell responses in children with autism. Brain Behav Immun 2011;25(5):840-9.

15. Ashwood P, Van Der Water JA. A review of autism and the immune response. Clin Dev Immunol 2004;11(2):165-74.

16. Kern JK, Geier DA, Audhya T, King PG, Skyes LK, Geier MR. Evidence of parallels between mercury intoxication and the brain pathology in autism. Ac Neurobiol Exp (Wars) 2012; 72(2):113-53.

17. Theoharides TC, Asadi S, Patel AB. Focal brain inflammation and autism. J Neuroinflammation 2013;10:46.

18. Ashwood P, Wills S, Van Der Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006; 80(1):1-15.

19. Parker-Athill EC, Tan J. Maternal immune-activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals 2010;18(2):113-28.

20. Goines P, Van Der Water J. The immune system role in the Biology of Autism. Curr Opin Neurol 2010;23(2):111-7.

21. Shaashua L, Sominsky L, Levy B, Sorski L, Reznick M, Page GG, et al. In vivo supression of plasma IL-12 levels by acute and chronic stress paradigms; potential mediating mechanisms and sex differences. Brain Behav Immun 2012; 26(6):996-1005.

22. Davis NO, Kollins SH. Treatment of co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics 2012;9(3):518-30.

23. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin- 17 in children with autism. J Neuroinflammation 2012;9:158.

24. Diano S, Hor vath TL. Anticonvulsant effects of leptin in epilepsy. J Clin Invest 2008;118(1):26-8.

25. Harvey J. Leptin: a multifaceted hormone in the central nervous system. Mol Neurobiol 2003;28(3):245-58.

26. Pessah IN, Seegal RF, Lein PJ, LaSalle J, Yee BK, Van Der, et al. Immunologic and neurodevelopmental susceptibilities of autism. Neurotoxicol 2008;29(3):532-45.

27. Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theoharides TC. Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatr 2012;12:89.